The Role of M1 Muscarinic Receptor Agonism of N-desmethylclozapine in the Unique Clinical Effects of Clozapine

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2004 Jul 20

PMID 15258717

Citations 71

Authors

D M Weiner

H Y Meltzer

I Veinbergs

E M Donohue

T A Spalding

T T Smith

N Mohell

S C Harvey

J Lameh

N Nash

K E Vanover

R Olsson

K Jayathilake

M Lee

A I Levey

U Hacksell

E S Burstein

R E Davis

M R Brann

Affiliations

Soon will be listed here.

Abstract

Rationale: Clozapine is a unique antipsychotic, with efficacy against positive symptoms in treatment-resistant schizophrenic patients, and the ability to improve cognition and treat the negative symptoms characteristic of this disease. Despite its unique clinical actions, no specific molecular mechanism responsible for these actions has yet been described.

Objectives And Methods: To comprehensively profile a large library of neuropsychiatric drugs, including most antipsychotics, at human monoamine receptors using R-SAT, an in vitro functional assay.

Results: Profiling revealed that N-desmethylclozapine (NDMC), the principal metabolite of clozapine, but not clozapine itself, is a potent and efficacious muscarinic receptor agonist, a molecular property not shared by any other antipsychotic. To further explore the role of NDMC muscarinic receptor agonist properties in mediating the physiological actions of clozapine, systemically administered NDMC was found to stimulate the phosphorylation of mitogen-activated protein kinase (MAP kinase) in mouse CA1 hippocampal neurons, an effect that was blocked by scopolamine, confirming central M1 muscarinic receptor agonist activity in vivo. Lastly, an analysis of clozapine and NDMC serum levels in schizophrenic patients indicated that high NDMC/clozapine ratios better predicted improvement in cognitive functioning and quality of life than the levels of either compound alone.

Conclusions: The muscarinic receptor agonist activities of NDMC are unique among antipsychotics, and provide a possible molecular basis for the superior clinical effects of clozapine pharmacotherapy.

Citing Articles

The effects of clinical and pharmacological factors on the ratio of clozapine to norclozapine in psychiatric patients.

Mach A, Wnorowska A, Siwek M, Wojnar M, Radziwon-Zaleska M Front Pharmacol. 2025; 15():1518739.

PMID: 39840091 PMC: 11746079. DOI: 10.3389/fphar.2024.1518739.

Clozapine and Pneumonia: Synthesizing the Link by Reviewing Existing Reports-A Systematic Review and Meta-Analysis.

Zhao V, Gong Y, Thomas N, Das S Medicina (Kaunas). 2025; 60(12.

PMID: 39768896 PMC: 11728434. DOI: 10.3390/medicina60122016.

Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review.

Moscou T, Veerman S Ther Adv Psychopharmacol. 2024; 14:20451253241302603.

PMID: 39650250 PMC: 11624563. DOI: 10.1177/20451253241302603.

Clinical and pharmacological factors influencing serum clozapine and norclozapine levels.

Mach A, Wnorowska A, Siwek M, Wojnar M, Radziwon-Zaleska M Front Pharmacol. 2024; 15:1356813.

PMID: 38601469 PMC: 11004283. DOI: 10.3389/fphar.2024.1356813.

Clozapine-Induced Severe Toxicity: Exploring the Pharmacokinetic Profile of Clozapine and Its Significance in Hemodynamic Instability - A Case Report.

Yu Z, Pi Y, Chen M, Dong D, Gu Q Int Med Case Rep J. 2024; 17:111-120.

PMID: 38348428 PMC: 10860498. DOI: 10.2147/IMCRJ.S444685.

References

Bonner T, Buckley N, Young A, Brann M . Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987; 237(4814):527-32. DOI: 10.1126/science.3037705. View

Weissman J, Ma J, Essex A, Gao Y, Burstein E . G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway. Oncogene. 2004; 23(1):241-9. DOI: 10.1038/sj.onc.1207014. View

Kane J, HONIGFELD G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9):789-96. DOI: 10.1001/archpsyc.1988.01800330013001. View

Shannon H, Rasmussen K, Bymaster F, Hart J, Peters S, Swedberg M . Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000; 42(3):249-59. DOI: 10.1016/s0920-9964(99)00138-3. View

Brauner-Osborne H, Ebert B, Brann M, Falch E, Krogsgaard-Larsen P . Functional partial agonism at cloned human muscarinic acetylcholine receptors. Eur J Pharmacol. 1996; 313(1-2):145-50. DOI: 10.1016/0014-2999(96)00501-8. View

Spalding T, Trotter C, Skjaerbaek N, Messier T, Currier E, Burstein E . Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol. 2002; 61(6):1297-302. DOI: 10.1124/mol.61.6.1297. View

Nordin C, Alme B, Bondesson U . CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study. Psychopharmacology (Berl). 1995; 122(2):104-7. DOI: 10.1007/BF02246083. View

Baldessarini R, Frankenburg F . Clozapine. A novel antipsychotic agent. N Engl J Med. 1991; 324(11):746-54. DOI: 10.1056/NEJM199103143241107. View

Gerber D, Sotnikova T, Gainetdinov R, Huang S, Caron M, Tonegawa S . Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A. 2001; 98(26):15312-7. PMC: 65026. DOI: 10.1073/pnas.261583798. View

10.

Weiner D, Levey A, Brann M . Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci U S A. 1990; 87(18):7050-4. PMC: 54680. DOI: 10.1073/pnas.87.18.7050. View

11.

Bymaster F, Carter P, Yamada M, Gomeza J, Wess J, Hamilton S . Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci. 2003; 17(7):1403-10. DOI: 10.1046/j.1460-9568.2003.02588.x. View

12.

Berkeley J, Gomeza J, Wess J, Hamilton S, Nathanson N, Levey A . M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. Mol Cell Neurosci. 2002; 18(5):512-24. DOI: 10.1006/mcne.2001.1042. View

13.

Kuoppamaki M, Syvalahti E, Hietala J . Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol. 1993; 245(2):179-82. DOI: 10.1016/0922-4106(93)90126-t. View

14.

Green M . What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996; 153(3):321-30. DOI: 10.1176/ajp.153.3.321. View

15.

Hagger C, Buckley P, Kenny J, Friedman L, Ubogy D, Meltzer H . Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993; 34(10):702-12. DOI: 10.1016/0006-3223(93)90043-d. View

16.

Bodick N, Offen W, Levey A, Cutler N, Gauthier S, Satlin A . Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997; 54(4):465-73. DOI: 10.1001/archneur.1997.00550160091022. View

17.

Gauch R, Michaelis W . The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e) (1,4)diazepine (clozapine) in mice, dogs and human subjects. Farmaco Prat. 1971; 26(11):667-81. View

18.

Lee M, Jayathilake K, Meltzer H . A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res. 1999; 37(1):1-11. DOI: 10.1016/s0920-9964(98)00145-5. View

19.

Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer H . Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993; 13(6):383-90. View

20.

Weiner D, Burstein E, Nash N, Croston G, Currier E, Vanover K . 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001; 299(1):268-76. View